Compare Sun Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PIRAMAL ENTERPRISES SUN PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 27.3 16.8 162.2% View Chart
P/BV x 2.4 1.1 220.5% View Chart
Dividend Yield % 0.7 1.7 40.9%  

Financials

 SUN PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
PIRAMAL ENTERPRISES
Mar-19
SUN PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs6793,303 20.6%   
Low Rs3751,797 20.9%   
Sales per share (Unadj.) Rs121.1716.5 16.9%  
Earnings per share (Unadj.) Rs13.479.7 16.8%  
Cash flow per share (Unadj.) Rs20.7107.9 19.2%  
Dividends per share (Unadj.) Rs2.7528.00 9.8%  
Dividend yield (eoy) %0.51.1 47.5%  
Book value per share (Unadj.) Rs172.61,477.5 11.7%  
Shares outstanding (eoy) m2,399.26184.45 1,300.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.43.6 122.3%   
Avg P/E ratio x39.432.0 123.2%  
P/CF ratio (eoy) x25.523.6 107.8%  
Price / Book Value ratio x3.11.7 177.0%  
Dividend payout %20.635.1 58.5%   
Avg Mkt Cap Rs m1,264,650470,292 268.9%   
No. of employees `00017.57.8 223.8%   
Total wages/salary Rs m59,67122,504 265.2%   
Avg. sales/employee Rs Th16,608.116,899.4 98.3%   
Avg. wages/employee Rs Th3,409.62,877.7 118.5%   
Avg. net profit/employee Rs Th1,833.81,879.9 97.5%   
INCOME DATA
Net Sales Rs m290,659132,153 219.9%  
Other income Rs m10,2553,128 327.8%   
Total revenues Rs m300,914135,281 222.4%   
Gross profit Rs m63,07666,290 95.2%  
Depreciation Rs m17,5335,202 337.1%   
Interest Rs m5,55344,097 12.6%   
Profit before tax Rs m50,24620,119 249.7%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0098,611 69.8%   
Profit after tax Rs m32,09314,701 218.3%  
Gross profit margin %21.750.2 43.3%  
Effective tax rate %12.042.8 27.9%   
Net profit margin %11.011.1 99.3%  
BALANCE SHEET DATA
Current assets Rs m310,692122,742 253.1%   
Current liabilities Rs m173,396310,810 55.8%   
Net working cap to sales %47.2-142.3 -33.2%  
Current ratio x1.80.4 453.7%  
Inventory Days Days9923 429.3%  
Debtors Days Days11239 287.2%  
Net fixed assets Rs m232,477116,904 198.9%   
Share capital Rs m2,399369 650.4%   
"Free" reserves Rs m411,691272,161 151.3%   
Net worth Rs m414,091272,530 151.9%   
Long term debt Rs m15,226270,196 5.6%   
Total assets Rs m646,938856,261 75.6%  
Interest coverage x10.01.5 690.1%   
Debt to equity ratio x01.0 3.7%  
Sales to assets ratio x0.40.2 291.1%   
Return on assets %5.86.9 84.7%  
Return on equity %7.85.4 143.7%  
Return on capital %10.212.4 81.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02515,200 434.4%   
Fx outflow Rs m38,6104,889 789.8%   
Net fx Rs m27,41510,312 265.9%   
CASH FLOW
From Operations Rs m21,965-115,975 -18.9%  
From Investments Rs m-6,813-8,265 82.4%  
From Financial Activity Rs m-27,305107,525 -25.4%  
Net Cashflow Rs m-8,442-16,650 50.7%  

Share Holding

Indian Promoters % 63.7 52.9 120.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 4.0 128.3%  
FIIs % 23.0 26.6 86.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 16.5 50.3%  
Shareholders   133,026 93,274 142.6%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  TTK HEALTHCARE  TORRENT PHARMA  PLETHICO PHARMA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

PIRAMAL ENTERPRISES Surges by 10%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Oct 22, 2019 | Updated on Oct 22, 2019

PIRAMAL ENTERPRISES share price has surged by 10% and its current market price is Rs 1,712. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index is PIRAMAL ENTERPRISES (up 10.0%). The top losers are BIOCON (down 0.3%) and ALKEM LABORATORIES (down 0.3%).

ASTRAZENECA PHARMA Surges by 5%; BSE HEALTHCARE Index Up 1.2% (Market Updates)

Oct 22, 2019 | Updated on Oct 22, 2019

ASTRAZENECA PHARMA share price has surged by 5% and its current market price is Rs 2,424. The BSE HEALTHCARE is up by 1.2%. The top gainers in the BSE HEALTHCARE Index are ASTRAZENECA PHARMA (up 5.5%) and PIRAMAL ENTERPRISES (up 7.2%). The top losers are GLENMARK PHARMA (down 0.2%) and SANOFI INDIA (down 0.2%).

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Oct 22, 2019 03:37 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS